Evaluation of clinical validity of the Rabin cone contrast test in normal phakic or pseudophakic eyes and severely dichromatic eyes.

Purpose: To evaluate the clinical validity of the Rabin cone contrast test (RCCT; Innova Systems, Inc.) in patients with normal phakic/pseudophakic eyes and severe dichromatic colour vision deficiency (CVD).

Methods: We evaluated age-related changes in the RCCT scores in 166 phakic eyes and 34 pseudophakic eyes and the RCCT sensitivity and specificity in 28 men with severe dichromatic CVD (10 with protanopia, 18 with deutanopia) and nine age-matched controls.

Capillary Dropout at the Retinal Nerve Fiber Layer Defect in Glaucoma: An Optical Coherence Tomography Angiography Study.

Purpose: To investigate the microvasculature changes of retinal nerve fiber layer (RNFL) defects in glaucoma.

Design: The study design is a case report.

Patients And Methods: Four glaucomatous eyes were included in this observational cross-sectional study.

Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.

Purpose: We evaluated the pharmacokinetics of intravitreally injected ranibizumab and aflibercept, and their effects on VEGF in the aqueous humor of vitrectomized and nonvitrectomized macaque eyes.

Methods: Intravitreal ranibizumab (IVR; 0.5 mg/50 μL) or intravitreal aflibercept (IVA; 2 mg/50 μL) was injected into the previously vitrectomized right eyes of three macaques and nonvitrectomized right eyes of three macaques.

Evaluation of acquired color vision deficiency in glaucoma using the Rabin cone contrast test.

Purpose: To evaluate acquired color vision deficiency in glaucoma by using the Rabin cone contrast test (RCCT).

Methods: Twenty-seven eyes of 27 patients with glaucoma (glaucoma group) and 27 eyes of 27 normal subjects (control group) were included in this study. Long (L), medium (M), and short (S) CCT scores (L CCTs, M CCTs, and S CCTs, respectively) were measured using the RCCT in both groups.

Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization.

Aim: To compare the effects of one intravitreal bevacizumab (IVB) injection with three monthly injections for myopic choroidal neovascularization.

Methods: Group A included 13 patients treated with one IVB injection; group B included 19 patients treated with three monthly 1.25-mg IVB injections.